Dr. Daniel B. Rosenbluth, MD

Dr. Rosenbluth practices at Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health.

Dr. Rosenbluth's NPI, 1548287055, was assigned on July 17, 2006. Dr. Rosenbluth graduated from Icahn School of Medicine at Mount Sinai in 1989. Dr. Rosenbluth holds Missouri license 101454.

Dr. Rosenbluth's primary practice is Barnes-Jewish Hospital, at One Barnes-Jewish Hospital Plaza, Saint Louis, MO 63110 in St. Louis City. The practice phone is (314) 747-3000. Dr. Rosenbluth also practices at Barnes-Jewish Hospital, 1 Barnes Jewish Hospital Plz, Saint Louis, MO 63110.

Dr. Rosenbluth's primary practice is Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health. Dr. Rosenbluth is also affiliated with Barnes-Jewish West County Hospital. The medical group on file is WashU Medicine Psychiatry. Dmand AI also links Dr. Rosenbluth to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rosenbluth practices, 4 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Rosenbluth's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Rosenbluth is licensed in Missouri.

CMS data shows 363 Medicare services from Dr. Rosenbluth across 6 procedure codes in 2024, for 200 Medicare patients. Medicare paid $30,089 for them.

CMS counts 200 Medicare patients who saw Dr. Rosenbluth in 2024. The largest group is 65 to 74, with 82 patients. 68% of them have high blood pressure, and 66% have copd. 28% are also on Medicaid. Their average risk score is 2.54, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rosenbluth's median patient age at 66, with 58% women.

In 2024, Dr. Rosenbluth wrote 1,927 Medicare Part D claims for 177 patients. 41% of them were for generic drugs. CMS names the drug for 1,702 of them, across 36 drugs with 11 or more claims each, at $10,591,114 in total drug cost. In 2023, CMS named 1,544 claims across 37 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Rosenbluth for performance year 2024, reported as part of a group. Dr. Rosenbluth accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 14 papers to Dr. Rosenbluth, published from 2011 to 2024. 2011 was the busiest year, with 2. The most frequent topics are Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator and Lung. Dr. Rosenbluth has published most often in J Cyst Fibros. Dr. Rosenbluth's most frequent co-authors are John P. Clancy, MD, Scott H. Donaldson, MD and Raksha Jain, MD.

Dmand AI links Dr. Rosenbluth to 1 clinical trial. Conditions studied include Cystic Fibrosis and Infant, Newborn, Diseases.

CMS Open Payments shows 55 general payments to Dr. Rosenbluth from 7 drug and device companies from 2016 to 2024. Consulting fees make up the largest share, 53% of the total. Vertex Pharmaceuticals Incorporated paid the most, $8,988.

Dr. Rosenbluth graduated from Icahn School of Medicine at Mount Sinai in 1989.